Phillip P. Chan - Dec 13, 2023 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role
Chief Executive Officer, Director
Signature
/s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan
Stock symbol
CTSO
Transactions as of
Dec 13, 2023
Transactions value $
$100,000
Form type
4
Date filed
12/15/2023, 04:30 PM
Previous filing
Jul 11, 2023
Next filing
Apr 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTSO Common Stock Purchase $100K +75.2K +7.57% $1.33 1.07M Dec 13, 2023 Direct F1, F2, F3, F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTSO Common Stock Warrant (Right to Buy) Purchase +26.3K 26.3K Dec 13, 2023 Common Stock 26.3K $2.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities were purchased by the reporting person in the registered direct offering of CytoSorbents Corporation (the "Company"), which closed on December 13, 2023. In the offering, each share of common stock, par value $0.001 per share (the "Common Stock") of the Company was purchased together with an accompanying warrant to purchase up to 0.35 shares of Common Stock, at a combined offering price of $1.33 per share of Common Stock and accompanying warrant.
F2 Includes: (i) the following restricted stock units ("RSUs") (which vest as to two-thirds of the award on the first anniversary of the date of grant and onethird of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 87,000 RSUs granted on July 7, 2023 and unvested as of the date hereof;
F3 (continued from footnote 2) (ii) the following RSUs that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
F4 (continued from footnote 3) (iii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into shares of Common Stock upon vesting: 26,334 RSUs granted on August 10, 2022 and unvested as of the date hereof; and
F5 (continued from footnote 4) (iv) 739,370 shares of Common Stock owned by the reporting person.